Announced
Completed
Oriental Fortune Capital led a $100m Series B round in Bao Pharmaceuticals.
Synopsis
Oriental Fortune Capital, a venture capital firm, led a $100m Series B round in Bao Pharmaceuticals, a biopharmaceutical company, with participation from Haitong Innovation and Guosheng Group-backed Sun Rock Capital. Shanghai-based recombinant protein and antibody drug specialist said that it will use the funds to drive the commercialization of core products in development and key clinical trials for new pipelines.
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
By continuing, you agree to our Terms & Conditions and our Data Privacy Policy
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.